Market Summary
USD832.56+0.15
Market Closed0.02%
REGN Alerts
REGN Stock Price
REGN RSI Chart
REGN Valuation
REGN Price/Sales (Trailing)
REGN Profitability
REGN Fundamentals
REGN Revenue
REGN Earnings
Price Action
52 Week Range
668.00847.50
(Low)(High)
Last 7 days
0.1%
Last 30 days
0.2%
Last 90 days
17.5%
Trailing 12 Months
19.8%
REGN Financial Health
REGN Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for REGN
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-08 | Schenkein David P | acquired | - | - | 240 | - |
2023-09-08 | Guarini Kathryn | acquired | - | - | 240 | - |
2023-09-01 | McCourt Marion | sold | -208,638 | 834 | -250 | evp commercial |
2023-08-24 | Van Plew Daniel P | sold | -5,216,070 | 841 | -6,197 | evp & general mgr, industrial |
2023-08-23 | POON CHRISTINE A | acquired | 3,360,670 | 273 | 12,280 | - |
2023-08-23 | Fenimore Christopher R. | sold (taxes) | -4,380,150 | 842 | -5,198 | svp controller |
2023-08-23 | Van Plew Daniel P | acquired | 8,819,880 | 381 | 23,125 | evp & general mgr, industrial |
2023-08-23 | Landry Robert E | sold | -188,212 | 844 | -223 | evp finance cfo |
2023-08-23 | Van Plew Daniel P | sold (taxes) | -14,264,500 | 842 | -16,928 | evp & general mgr, industrial |
2023-08-23 | Fenimore Christopher R. | acquired | 2,797,620 | 399 | 7,000 | svp controller |
Which funds bought or sold REGN recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-26 | BROOKFIELD Corp /ON/ | added | 8.68 | -1,111,260 | 21,287,500 | 0.08% |
2023-09-21 | Baystate Wealth Management LLC | unchanged | - | -825 | 5,748 | -% |
2023-09-20 | BARCLAYS PLC | added | 58.25 | 55,605,000 | 200,462,000 | 0.13% |
2023-09-14 | IMS Capital Management | unchanged | - | -28,877 | 201,191 | 0.11% |
2023-09-12 | Farther Finance Advisors, LLC | added | 175 | 124,666 | 213,406 | 0.05% |
2023-09-05 | Delos Wealth Advisors, LLC | unchanged | - | -5,569 | 38,802 | 0.05% |
2023-09-01 | Portside Wealth Group, LLC | new | - | 285,979 | 285,979 | 0.05% |
2023-08-24 | Alberta Investment Management Corp | added | 131 | 2,638,100 | 5,211,570 | 0.05% |
2023-08-24 | Arlington Capital Management, Inc. | sold off | -100 | -227,603 | - | -% |
2023-08-23 | Rehmann Capital Advisory Group | added | 2.89 | -37,067 | 332,684 | 0.03% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
REGN Alerts
Schedule 13G FIlings of Regeneron Pharmaceuticals
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 13, 2023 | capital world investors | 5.9% | 6,315,819 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.15% | 8,722,448 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 8.6% | 9,166,817 | SC 13G/A | |
| Jan 11, 2023 | jpmorgan chase & co | 5.6% | 6,101,044 | SC 13G | |
| Feb 11, 2022 | capital world investors | 5.1% | 5,391,870 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 7.72% | 8,158,515 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 9.1% | 9,610,871 | SC 13G/A | |
| Feb 16, 2021 | capital world investors | 6.7% | 7,017,122 | SC 13G/A |
Recent SEC filings of Regeneron Pharmaceuticals
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 27, 2023 | SC 13D/A | 13D - Major Acquisition | |
| Sep 25, 2023 | SC TO-T/A | SC TO-T/A | |
| Sep 12, 2023 | 3 | Insider Trading | |
| Sep 12, 2023 | 3 | Insider Trading | |
| Sep 12, 2023 | 4 | Insider Trading | |
| Sep 12, 2023 | 4 | Insider Trading | |
| Sep 12, 2023 | SC TO-T/A | SC TO-T/A | |
| Sep 08, 2023 | 8-K/A | Current Report | |
| Sep 08, 2023 | SC TO-T/A | SC TO-T/A | |
| Sep 08, 2023 | 8-K | Current Report |
REGN Fair Value
Loading...
Peers (Alternatives to Regeneron Pharmaceuticals)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABBV | 270.6B | 56.0B | 3.87% | 9.15% | 31.15 | 4.83 | -2.31% | -31.27% |
BGNE | 264.5B | 1.8B | -4.90% | 38.70% | -152.67 | 146.06 | 69.45% | 14.65% |
VRTX | 90.1B | 9.5B | -0.55% | 22.80% | 26.79 | 9.48 | 13.83% | 5.33% |
REGN | 89.1B | 12.7B | 0.20% | 19.79% | 20.72 | 7.03 | -10.94% | -24.40% |
ALNY | 22.1B | 1.2B | -7.72% | -12.71% | -20.77 | 17.85 | 39.94% | -8.44% |
SRPT | 11.5B | 1.0B | 4.08% | 13.95% | -12.68 | 11.47 | 20.15% | -79.16% |
UTHR | 10.9B | 2.1B | 2.86% | 12.91% | 12.51 | 5.17 | 18.01% | 38.16% |
| MID-CAP | ||||||||
BPMC | 3.0B | 225.6M | 1.84% | -24.74% | -5.46 | 13.42 | -2.11% | 21.02% |
MDGL | 2.8B | - | -16.23% | 132.76% | -8.48 | - | - | -28.88% |
RARE | 2.6B | 402.9M | 0.63% | -8.39% | -3.66 | 6.55 | 20.50% | -42.46% |
MRTX | 2.4B | 27.2M | 10.98% | -38.97% | -3.26 | 88.36 | - | -14.43% |
| SMALL-CAP | ||||||||
CYTK | 3.1B | - | -16.61% | -39.22% | -7.31 | 33.28 | 34.30% | -149.91% |
CPRX | 1.3B | 302.9M | -14.36% | -1.93% | 11.22 | 4.28 | 77.72% | 112.02% |
MGNX | 291.7M | 152.5M | -6.92% | 34.57% | 39.16 | 1.91 | 127.84% | 103.41% |
CRBP | 28.1M | - | -6.20% | 3967.91% | -0.61 | - | - | -31.51% |
Regeneron Pharmaceuticals News
Returns for REGN
Cumulative Returns on REGN
10.5%
10-Year Cumulative Returns
10.3%
7-Year Cumulative Returns
15.6%
5-Year Cumulative Returns
13.2%
3-Year Cumulative Returns
Risks for REGN
What is the probability of a big loss on REGN?
61.5%
Probability that Regeneron Pharmaceuticals stock will be more than 20% underwater in next one year
25.4%
Probability that Regeneron Pharmaceuticals stock will be more than 30% underwater in next one year.
0%
Probability that Regeneron Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does REGN drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Regeneron Pharmaceuticals was unfortunately bought at previous high price.
Drawdowns
Financials for Regeneron Pharmaceuticals
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 2.4% | 12,671 | 12,370 | 12,173 | 13,710 | 14,227 | 16,508 | 16,072 | 13,543 | 12,384 | 9,198 | 8,497 | 7,938 | 7,387 | 7,013 | 6,558 | 6,622 | 6,542 | 6,572 | 6,711 | 6,365 | 6,203 |
| Costs and Expenses | 5.0% | 8,337 | 7,943 | 7,434 | 7,478 | 7,372 | 7,416 | 7,125 | 6,069 | 5,704 | 5,208 | 4,921 | 4,852 | 4,617 | 4,583 | 4,348 | 4,370 | 4,401 | 4,125 | 4,176 | 4,010 | 3,914 |
| S&GA Expenses | 7.8% | 2,443 | 2,267 | 2,116 | 2,015 | 1,931 | 1,869 | 1,825 | 1,569 | 1,451 | 1,384 | 1,346 | 1,494 | 1,472 | 1,418 | 1,342 | 952 | 1,017 | 1,087 | 1,127 | 1,475 | 1,412 |
| R&D Expenses | 7.6% | 4,141 | 3,850 | 3,593 | 3,287 | 3,041 | 2,961 | 2,860 | 2,779 | 2,798 | 2,806 | 2,647 | 2,543 | 2,384 | 2,548 | 2,450 | 1,782 | 1,813 | 1,456 | 1,469 | 2,113 | 2,086 |
| EBITDA | -100.0% | - | 5,086 | 5,260 | 6,409 | 6,696 | 9,483 | 9,669 | 8,378 | 7,558 | 4,707 | 4,103 | 3,753 | 3,498 | 2,796 | 2,670 | 2,445 | 2,295 | 2,707 | 2,730 | 2,599 | 2,530 |
| EBITDA Margin | -100.0% | - | 0.41* | 0.43* | 0.47* | 0.45* | 0.57* | 0.60* | 0.62* | 0.61* | 0.51* | 0.48* | 0.47* | 0.47* | 0.38* | 0.37* | 0.33* | 0.32* | 0.39* | 0.41* | 0.41* | 0.41* |
| Interest Expenses | 9.1% | 70.00 | 64.00 | 59.00 | 56.00 | 55.00 | 56.00 | 57.00 | 58.00 | 70.00 | 65.00 | 57.00 | 49.00 | 30.00 | 29.00 | 30.00 | 31.00 | 31.00 | 29.00 | 28.00 | 27.00 | 25.00 |
| Earnings Before Taxes | 2.6% | 4,775 | 4,656 | 4,859 | 6,038 | 6,344 | 9,134 | 9,326 | 8,047 | 7,229 | 4,395 | 3,810 | 3,476 | 3,246 | 2,552 | 2,429 | 2,216 | 2,083 | 2,514 | 2,554 | 2,432 | 2,362 |
| EBT Margin | -100.0% | - | 0.38* | 0.40* | 0.44* | 0.42* | 0.55* | 0.58* | 0.59* | 0.58* | 0.48* | 0.45* | 0.44* | 0.44* | 0.35* | 0.33* | 0.30* | 0.29* | 0.36* | 0.38* | 0.38* | 0.38* |
| Net Income | 2.8% | 4,299 | 4,183 | 4,338 | 5,370 | 5,687 | 7,934 | 8,075 | 6,996 | 6,205 | 4,004 | 3,513 | 3,156 | 2,984 | 2,279 | 2,116 | 2,144 | 2,069 | 2,428 | 2,445 | 1,798 | 1,591 |
| Net Income Margin | -100.0% | - | 0.34* | 0.36* | 0.39* | 0.38* | 0.48* | 0.50* | 0.52* | 0.50* | 0.44* | 0.41* | 0.40* | 0.40* | 0.31* | 0.29* | 0.29* | 0.29* | 0.35* | 0.36* | 0.28* | 0.26* |
| Free Cashflow | -100.0% | - | 4,281 | 5,015 | 5,668 | 8,452 | 8,515 | 7,081 | 5,940 | 2,272 | 2,589 | 2,618 | 2,175 | 2,986 | 2,231 | 2,430 | 2,371 | 2,267 | 2,473 | 2,195 | 2,033 | 1,995 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 2.0% | 30,658 | 30,060 | 29,215 | 27,678 | 27,206 | 26,349 | 25,435 | 23,672 | 21,486 | 17,772 | 17,163 | 16,084 | 14,429 | 15,758 | 14,805 | 13,939 | 13,174 | 12,855 | 11,735 | 10,806 | 9,952 |
| Current Assets | 0.1% | 16,923 | 16,909 | 15,884 | 15,429 | 15,530 | 14,306 | 14,015 | 13,775 | 13,338 | 10,055 | 9,779 | 9,098 | 7,860 | 8,644 | 7,689 | 7,109 | 6,651 | 6,929 | 6,448 | 5,720 | 4,815 |
| Cash Equivalents | -50.5% | 1,937 | 3,916 | 3,106 | 3,491 | 3,395 | 3,346 | 2,898 | 3,432 | 2,072 | 1,438 | 2,194 | 1,573 | 1,992 | 2,208 | 1,630 | 1,385 | 1,046 | 1,709 | 1,480 | 1,088 | 918 |
| Inventory | 3.4% | 2,508 | 2,425 | 2,402 | 2,412 | 2,219 | 1,992 | 1,951 | 2,054 | 1,984 | 2,165 | 1,917 | 1,802 | 1,641 | 1,481 | 1,416 | 1,344 | 1,317 | 1,209 | 1,151 | 1,040 | 929 |
| Net PPE | - | - | - | - | 3,704 | 3,638 | 3,556 | 3,482 | 3,396 | 3,359 | 3,263 | 3,222 | 3,138 | 3,031 | 2,945 | 2,890 | 2,771 | 2,677 | 2,613 | 2,576 | 2,524 | 2,462 |
| Liabilities | 1.1% | 6,640 | 6,565 | 6,551 | 6,239 | 6,518 | 6,434 | 6,666 | 6,414 | 6,359 | 5,795 | 6,138 | 5,959 | 5,371 | 3,625 | 3,716 | 3,435 | 3,418 | 3,410 | 2,977 | 2,937 | 2,766 |
| Current Liabilities | 0.1% | 3,104 | 3,100 | 3,141 | 2,879 | 3,034 | 3,008 | 3,933 | 3,715 | 3,732 | 3,218 | 2,697 | 2,338 | 3,702 | 2,055 | 2,097 | 1,765 | 1,713 | 1,511 | 1,443 | 1,417 | 1,331 |
| LT Debt, Non Current | 0.0% | 1,982 | 1,982 | 1,981 | 1,981 | 1,981 | 1,980 | 1,980 | 1,980 | 1,979 | 1,979 | 1,979 | 1,978 | - | - | - | - | - | - | - | - | - |
| Shareholder's Equity | 2.2% | 24,018 | 23,495 | 22,664 | 21,439 | 20,688 | 19,915 | 18,769 | 17,258 | 15,127 | 11,977 | 11,025 | 10,126 | 9,057 | 12,133 | 11,090 | 10,504 | 9,756 | 9,445 | 8,757 | 7,868 | 7,186 |
| Retained Earnings | 4.0% | 25,093 | 24,125 | 23,307 | 22,110 | 20,794 | 19,942 | 18,968 | 16,739 | 15,107 | 12,008 | 10,893 | 9,744 | 8,902 | 8,004 | 7,380 | 6,588 | 5,918 | 5,725 | 5,254 | 4,434 | 3,839 |
| Additional Paid-In Capital | 2.7% | 10,889 | 10,598 | 9,949 | 9,518 | 9,120 | 8,754 | 8,088 | 7,919 | 7,226 | 6,888 | 6,716 | 6,593 | 6,263 | 5,211 | 4,429 | 4,388 | 4,264 | 4,161 | 3,912 | 3,841 | 3,713 |
| Shares Outstanding | -0.1% | 107 | 107 | - | 107 | 108 | 107 | - | 106 | 105 | 105 | - | 106 | 110 | 110 | - | 109 | 109 | 109 | - | 108 | 108 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 10.7% | 4,739 | 4,281 | 5,015 | 5,668 | 8,452 | 8,515 | 7,081 | 5,940 | 2,272 | 2,589 | 2,618 | 2,175 | 2,986 | 2,231 | 2,430 | 2,371 | 2,267 | 2,473 | 2,195 | 2,033 | 1,995 |
| Share Based Compensation | 5.3% | 839 | 797 | 725 | 681 | 652 | 638 | 602 | 535 | 499 | 457 | 432 | 444 | 460 | 462 | 464 | 458 | 452 | 453 | 427 | 428 | 441 |
| Cashflow From Investing | -85.2% | -4,288 | -2,315 | -3,784 | -3,939 | -6,570 | -6,031 | -5,384 | -3,677 | -2,014 | -686 | -70.60 | 26.00 | 595 | -1,694 | -2,027 | -2,085 | -2,164 | -1,813 | -1,463 | -1,532 | -1,605 |
| Cashflow From Financing | -36.7% | -1,909 | -1,396 | -1,009 | -1,668 | -557 | -574 | -1,005 | -404 | -177 | -2,672 | -1,970 | -2,010 | -2,633 | -36.40 | -252 | 11.00 | 25.00 | 29.00 | -77.10 | -204 | -216 |
| Buy Backs | 13.5% | 2,761 | 2,432 | 2,083 | 2,526 | 1,803 | 1,698 | 1,645 | 1,184 | 1,094 | 5,877 | 5,847 | 5,755 | 5,674 | 602 | 276 | 29.00 | 14.00 | 14.00 | 4.00 | 4.00 | - |
REGN Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues: | ||||
| Revenues | $ 3,158.1 | $ 2,857.2 | $ 6,320.2 | $ 5,822.3 |
| Expenses: | ||||
| Research and development | 1,085.3 | 794.3 | 2,186.5 | 1,638.1 |
| Acquired in-process research and development | 0.0 | 197.0 | 56.1 | 225.1 |
| Selling, general, and administrative | 652.0 | 476.3 | 1,253.1 | 926.3 |
| Other operating (income) expense, net | (0.6) | (17.4) | (1.1) | (37.6) |
| Total Expenses | 2,141.6 | 1,747.3 | 4,357.0 | 3,453.9 |
| Income from operations | 1,016.5 | 1,109.9 | 1,963.2 | 2,368.4 |
| Other income (expense): | ||||
| Other income (expense), net | 85.3 | (133.6) | 14.6 | (317.4) |
| Interest expense | (18.9) | (13.1) | (36.9) | (26.7) |
| Total other income (expense) | 66.4 | (146.7) | (22.3) | (344.1) |
| Income before income taxes | 1,082.9 | 963.2 | 1,940.9 | 2,024.3 |
| Income tax expense | 114.5 | 111.1 | 154.7 | 198.7 |
| Net income | $ 968.4 | $ 852.1 | $ 1,786.2 | $ 1,825.6 |
| Net income per share - basic (in dollars per share) | $ 9.05 | $ 7.90 | $ 16.69 | $ 17.01 |
| Net income per share - diluted (in dollars per share) | $ 8.50 | $ 7.47 | $ 15.68 | $ 16.07 |
| Weighted average shares outstanding - basic (in shares) | 107.0 | 107.9 | 107.0 | 107.3 |
| Weighted average shares outstanding - diluted (in shares) | 113.9 | 114.0 | 113.9 | 113.6 |
| Statements of Comprehensive Income | ||||
| Net income | $ 968.4 | $ 852.1 | $ 1,786.2 | $ 1,825.6 |
| Other comprehensive income (loss), net of tax: | ||||
| Unrealized (loss) gain on debt securities | (15.7) | (53.7) | 41.5 | (198.6) |
| Loss on foreign currency translation | (0.4) | 0.0 | (0.4) | 0.0 |
| Unrealized gain on cash flow hedges | 0.0 | 0.0 | 0.0 | 1.0 |
| Comprehensive income | 952.3 | 798.4 | 1,827.3 | 1,628.0 |
| Net product sales | ||||
| Revenues: | ||||
| Revenues | 1,772.1 | 1,754.4 | 3,440.1 | 3,393.0 |
| Expenses: | ||||
| Cost of goods, collaboration and contract manufacturing | 192.4 | 149.2 | 400.8 | 356.5 |
| Collaboration revenue | ||||
| Revenues: | ||||
| Revenues | 1,316.7 | 1,043.6 | 2,694.8 | 2,276.1 |
| Other revenue | ||||
| Revenues: | ||||
| Revenues | 69.3 | 59.2 | 185.3 | 153.2 |
| Cost of collaboration and contract manufacturing | ||||
| Expenses: | ||||
| Cost of goods, collaboration and contract manufacturing | $ 212.5 | $ 147.9 | $ 461.6 | $ 345.5 |
REGN Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 1,937.2 | $ 3,105.9 |
| Marketable securities | 6,990.5 | 4,636.4 |
| Accounts receivable, net | 5,121.3 | 5,328.7 |
| Inventories | 2,507.7 | 2,401.9 |
| Prepaid expenses and other current assets | 366.3 | 411.2 |
| Total current assets | 16,923.0 | 15,884.1 |
| Marketable securities | 6,327.2 | 6,591.8 |
| Property, plant, and equipment, net | 3,922.6 | 3,763.0 |
| Intangible assets, net | 953.0 | 915.5 |
| Deferred tax assets | 2,138.5 | 1,723.7 |
| Other noncurrent assets | 393.2 | 336.4 |
| Total assets | 30,657.5 | 29,214.5 |
| Current liabilities: | ||
| Accounts payable | 547.3 | 589.2 |
| Accrued expenses and other current liabilities | 2,176.0 | 2,074.2 |
| Deferred revenue | 381.1 | 477.9 |
| Total current liabilities | 3,104.4 | 3,141.3 |
| Long-term debt | 1,982.2 | 1,981.4 |
| Finance lease liabilities | 720.0 | 720.0 |
| Deferred revenue | 116.2 | 69.8 |
| Other noncurrent liabilities | 716.8 | 638.0 |
| Total liabilities | 6,639.6 | 6,550.5 |
| Stockholders' equity: | ||
| Preferred Stock, par value $.01 per share; 30.0 shares authorized; issued and outstanding - none | 0.0 | 0.0 |
| Additional paid-in capital | 10,888.5 | 9,949.3 |
| Retained earnings | 25,092.9 | 23,306.7 |
| Accumulated other comprehensive loss | (197.7) | (238.8) |
| Treasury Stock, at cost; 24.5 shares in 2023 and 22.6 shares in 2022 | (11,765.9) | (10,353.3) |
| Total stockholders' equity | 24,017.9 | 22,664.0 |
| Total liabilities and stockholders' equity | 30,657.5 | 29,214.5 |
| Class A Stock | ||
| Stockholders' equity: | ||
| Common stock | 0.0 | 0.0 |
| Common Stock | ||
| Stockholders' equity: | ||
| Common stock | $ 0.1 | $ 0.1 |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.